Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-010 OLE in Focal Epilepsy
NCT04529954Phase 2Terminated
- Sponsor
- Cerebral Therapeutics
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of valproic acid in temporal lobe epilepsy (TLE), sponsored by Cerebral Therapeutics. Started Jan 2021; status: terminated.
02
Drugs
valproic acid
03
Conditions
temporal lobe epilepsy (TLE)
Beyond the preview
Go deeper on NCT04529954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529954.